PMID- 36706590 OWN - NLM STAT- MEDLINE DCOM- 20230308 LR - 20230308 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 116 DP - 2023 Mar TI - Putrescine accelerates the differentiation of bone marrow derived dendritic cells via inhibiting phosphorylation of STAT3 at Tyr705. PG - 109739 LID - S1567-5769(23)00062-0 [pii] LID - 10.1016/j.intimp.2023.109739 [doi] AB - Dendritic cells (DCs) play pivotal roles in immune responses. The differentiation and function of DCs are regulated by environmental metabolites. Putrescine is ubiquitous in various metabolic microenvironments and its immunoregulation has been of increasing interest. However, the mechanisms associated with its DC-induced immunoregulation remain unclear. In this study, we found putrescine promoted induction of immature bone marrow derived DCs (BMDCs), along with the increased phagocytosis and migration, and altered cytokine secretion in immature BMDCs. Transcriptomic profiles indicated significantly impaired inflammatory-related pathways, elevated oxidative phosphorylation, and decreased p-STAT3 (Tyr705) expression. Additionally, putrescine performed minor influence on the lipopolysaccharide (LPS)-induced maturation of BMDCs but significantly impaired LPS-induced DC-elicited allogeneic T-cell proliferation as well as the cytokine secretion. Furthermore, molecular docking and dynamics on the conjugation between putrescine and STAT3 revealed that putrescine could be stably bound to the hydrophilic cavity in STAT3 and performed significant influence on the Tyr705 phosphorylation. CUT&Tag analysis uncovered altered motifs, downregulated IFN-gamma response, and upregulated p53 pathway in Putrescine group compared with Control group. In summary, our results demonstrated for the first time that putrescine might accelerate the differentiation of BMDCs by inhibiting the phosphorylation of STAT3 at Tyr705. Given that both DCs and putrescine have ubiquitous and distinct roles in various immune responses and pathogeneses, our findings may provide more insights into polyamine immunoregulation on DCs, as well as distinct strategies in the clinical utilization of DCs by targeting polyamines. CI - Copyright (c) 2023 Elsevier B.V. All rights reserved. FAU - Huang, Panpan AU - Huang P AD - Department of Immunology, Binzhou Medical University, Yantai, China. FAU - Wang, Mengyang AU - Wang M AD - Department of Immunology, Binzhou Medical University, Yantai, China. FAU - Lu, Zixuan AU - Lu Z AD - Department of Immunology, Binzhou Medical University, Yantai, China. FAU - Shi, Shaojie AU - Shi S AD - Department of Immunology, Binzhou Medical University, Yantai, China. FAU - Wei, Xia AU - Wei X AD - Department of Immunology, Binzhou Medical University, Yantai, China. FAU - Bi, Chenxiao AU - Bi C AD - Department of Immunology, Binzhou Medical University, Yantai, China. FAU - Wang, Guoyan AU - Wang G AD - Medical Laboratory Science, Yantai Affiliated Hospital of ao'deBinzhou Medical University, Yantai, China. FAU - Liu, Hong AU - Liu H AD - The 2nd Medical College of Binzhou Medical University, Binzhou Medical University, Yantai, China. FAU - Hu, Tao AU - Hu T AD - Department of Immunology, Binzhou Medical University, Yantai, China. Electronic address: taohu@bzmc.edu.cn. FAU - Wang, Bin AU - Wang B AD - Department of Immunology, Binzhou Medical University, Yantai, China. Electronic address: bwang_bzmc@bzmc.edu.cn. LA - eng PT - Journal Article DEP - 20230126 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - V10TVZ52E4 (Putrescine) RN - 0 (Lipopolysaccharides) RN - 0 (Cytokines) SB - IM MH - Phosphorylation MH - *Putrescine/pharmacology/metabolism MH - *Lipopolysaccharides/metabolism MH - Bone Marrow MH - Molecular Docking Simulation MH - Cell Differentiation MH - Cells, Cultured MH - Cytokines/metabolism MH - Dendritic Cells MH - Bone Marrow Cells/metabolism OTO - NOTNLM OT - DC OT - Mitochondrial respiratory activity OT - Putrescine OT - STAT3 OT - Th2 response COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/28 06:00 MHDA- 2023/03/09 06:00 CRDT- 2023/01/27 18:12 PHST- 2022/11/11 00:00 [received] PHST- 2023/01/12 00:00 [revised] PHST- 2023/01/12 00:00 [accepted] PHST- 2023/01/28 06:00 [pubmed] PHST- 2023/03/09 06:00 [medline] PHST- 2023/01/27 18:12 [entrez] AID - S1567-5769(23)00062-0 [pii] AID - 10.1016/j.intimp.2023.109739 [doi] PST - ppublish SO - Int Immunopharmacol. 2023 Mar;116:109739. doi: 10.1016/j.intimp.2023.109739. Epub 2023 Jan 26.